Enterprise Advisory Group
The Global HIV Vaccine Enterprise Advisory Group (EAG) was established in 2019. It provides strategic and scientific advice on Enterprise activities that best meet the needs of the HIV vaccine research and development field and enable partnerships to deliver on the objectives of the Enterprise.
The EAG is made up of eight to 12 members with deep knowledge of, and strong connections across, the HIV vaccine field. The EAG reflects both gender and geographic diversity and includes civil society and community representatives.